Science's Survey Criteria Included a Focus on Research and Respect for
INDIANAPOLIS, Oct. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has made the list of Top 20 biopharmaceutical employers, according to the prestigious peer-reviewed journal Science. Science's 2008 survey polled nearly 4,000 employees from 500 employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. This year Lilly ranks number 10 on the list, up one position from last year's survey.
"At Lilly, our mission is to deliver innovative medicines for some of the world's most urgent unmet medical needs," said Steven Paul, M.D., executive vice president of science and technology, and president of Lilly Research Laboratories. "Core to our pipeline performance is the robust research environment here at Lilly, including excellence in both basic scientific and clinical research. Our world-renowned scientific talent has allowed Lilly to establish what we believe to be one of the best mid-stage pipelines in the industry, including 50 unique medicines - an all-time high for the company."
The web-based survey aims to determine the most reputable employers in the life science industries based on 23 characteristics, including among others, treating employees with respect, financial strength, easy adaptation to change, and a research-driven environment. The survey results appeared in today's issue of Science.
"It is an honor for Lilly to be recognized as one of the industry's top employers based on these important criteria," said John Lechleiter, Ph.D., Lilly president and chief executive officer. "Respect for people has always been a core value of Eli Lilly and Company, and this acknowledgement underscores Lilly's commitment to our employees and the patients we serve."
Approximately 25 percent of Lilly's 2007 sales came from biotech medicines; this makes the biotech portion of the company's business the equivalent of the world's fifth largest biotech company. Biotech molecules also represent approximately one-third of the company's current pipeline including potential treatments targeting Alzheimer's disease, cancer and diabetes.
Published by the American Association for the Advancement of Science (AAAS), Science ranks as the world's largest general science journal. Each week, Science provides more than 130,000 global subscribers with peer-reviewed original research, scientific research articles, science and research news and more. Science also produces a freely accessible careers website, ScienceCareers.org, offering thousands of job listings, career advice and more.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved